K. Krieglstein et K. Unsicker, PROTEIN FROM CHROMAFFIN GRANULES PROMOTES SURVIVAL OF MESENCEPHALIC DOPAMINERGIC-NEURONS BY AN EGF-RECEPTOR LIGAND-MEDIATED MECHANISM, Journal of neuroscience research, 48(1), 1997, pp. 18-30
Chromaffin cells grafted to the brain of animals with experimental par
kinsonism and patients with Parkinson's disease can restore nigrostria
tal functions. Mechanisms underlying these beneficial effects are unkn
own, but may include growth factors rather than the minute amounts of
dopamine (DA) liberated from chromaffin cells. We now report that prot
ein from chromaffin granules, which release their contents by exocytos
is, promotes survival and uptake of H-3-DA of mesencephalic DAergic ne
urons in vitro and protect against N-methylpyridinium ion toxicity. Th
is neurotrophic effect is accompanied by cell proliferation and mediat
ed by astroglial cells induced in these cultures. Inhibition of cell p
roliferation and concomitant astrogliosis by 5-fluorodeoxyuridine and
alpha-aminoadipic acid abolishes the trophic effect. Two highly specif
ic inhibitors of the epidermal growth factor receptor (EGFR) signal tr
ansduction pathway, 4,5-dianilinophthalimide (10 mu M) and tyrphostin
B56 (10 mu M), selectively block the neurotrophic capacity of chromaff
in granule protein. As expected, they also block the mitogenic effects
of EGF and TGF-alpha. However, these two mitogens do not mimic the pr
onounced mitogenic and trophic actions of chromaffin granule protein,
Culture medium conditioned by mesencephalic cells pretreated with chro
maffin granule protein promotes survival of DAergic neurons without in
creasing numbers of astroglial cells. The effective molecule is unlike
ly to be glial cell line-derived neurotrophic factor, whose mRNA is no
t detectable in cultures treated with chromaffin granule protein. We c
onclude that chromaffin granules contain a putatively novel growth fac
tor, which signals through the EGFR and may be responsible for the kno
wn protective and restorative actions of chromaffin cell grafts to the
lesioned nigrostriatal system. (C) 1997 Wiley-Liss, Inc.